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day 7; and left ventricular ejection fraction was determined
by radionuclide ventriculography on day 30. Clinical out-
come was monitored for six months. The study was sup-
ported by Wyeth Pharmaceuticals and presented by Jean-
Francois Tanguay of the Montreal Heart Institute
(Montreal, Quebec, Canada). The study failed to show any
significant effect of any dose of rPSGL-Ig on infarct size,
ejection fraction, and stroke/death/MI at 30 or 180 days.
Furthermore, and contrary to expectation, there was a
significant prolongation of time to ST-segment resolution
with increasing doses of rPSGL-Ig (p  0.008). Therefore,
this study failed to show any benefit with adjunctive use of
a novel P-selectin antagonist, and adds to a large body of
clinical trial data (conducted at an astronomical expense)
that have failed to show any benefit from any intervention
designed to address the so-called “reperfusion injury” de-
spite promising preclinical findings. These observations
continue to question the very existence of so-called “reper-
fusion injury,” as suggested by elegant experimental studies
of William Ganz at Cedars Sinai Medical Center (Los
Angeles, California) reported several years ago.
Regional angiogenesis with vascular endothelial growth
factor (VEGF): the RAVE trial. The concept of thera-
peutic angiogenesis for relief of ischemia, using angiogenic
growth factor gene transfer, first pioneered by the late Dr.
Jeffrey Isner, continues to be explored despite inconsistent
and conflicting results. The RAVE trial was a double-blind,
randomized, placebo-controlled trial to assess the safety and
efficacy of locally administered adenovirus-mediated
VEGF-121 (Ad-VEGF-121) gene transfer for unilateral
peripheral vascular disease in patients with severe disabling
intermittent claudication. The study was presented by Dr.
Sanjay Rajagopalan of the University of Michigan (Ann
Arbor, Michigan). Twenty local and ipsilateral intramuscu-
lar injections of either low dose or high dose of Ad-VEGF-
121 were compared with placebo injections in 105 patients
with severely symptomatic peripheral vascular disease con-
fined to one lower extremity. The primary end point was
safety and peak walking time at 12 weeks after randomiza-
tion. Secondary end points included ankle-brachial index
and peak walking time at 26 and 52 weeks.
The Ad-VEGF-121 therapy resulted in a dose-
dependent increase in leg edema (nearly 30% at high dose)
without any excess of cellulitis or liver function abnormal-
ities. However, Ad-VEGF-121, at any dose, failed to
produce any significant improvement over placebo in the
primary end point. Placebo-treated patients showed a 20%
increase in peak walking time at 12 weeks, which was not
significantly different from the 30% and 20% increases
experienced by low- and high-dose gene therapy recipients,
respectively. Similarly, there was no significant difference in
secondary end points or any other quality-of-life measures
between placebo and gene therapy recipients. These results
from the largest placebo-controlled adenoviral gene transfer
trial in cardiovascular disease to date were quite disappoint-
ing, adding to the uncertainty of this seemingly biologically
plausible and promising approach for refractory organ isch-
emia. The lack of beneficial effects may have been due to an
inadequate dose of Ad-VEGF-121, limited transcription of
the therapeutic gene, and/or limited duration of gene
transcription, which has been a problem with adenoviral
vectors. Whether better vectors, different angiogenic growth
factors, or different delivery systems will ultimately allow
realization of the promise of angiogenic gene therapy
remains an open question for now.
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The Vascular-Hypertension-Prevention (VHP) track
bridges the best data from vascular biology, thrombosis,
cardiovascular epidemiology, hypertension, and lipid-
modifying clinical trials and offers insights into optimal
treatment of coronary, cerebrovascular, and peripheral arte-
rial disease (PAD). This is a form of “translational medi-
cine” that extends knowledge “from the vascular endothe-
lium to clinical cardiovascular events.” The VHP track has
demonstrated that a better understanding of vascular biol-
ogy can improve cardiovascular health. New insights from
clinical practice can guide a search for biologic mechanisms,
just as improved understanding of vascular mechanisms can
guide improved practice. Abstracts in this arena now rep-
resent an increasingly large component (18%) of the Annual
Scientific Sessions.
THE FIRST VASCULAR SPOTLIGHT SESSION
In recognition of rapid scientific expansion, broad scope,
and clinical relevance of the VHP initiative, the meeting
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included a new “Vascular Spotlight” session. This year’s
Spotlight Session integrated four components, entitled
“From Vascular Biology to Vascular Pathophysiology,”
which reviewed endothelial biology and histopathology of
atherosclerosis; “From Vascular Pathophysiology to Vascu-
lar Disease,” which reviewed cardiovascular risk assessments
as well as new insights regarding the treatment of hyper-
tension, hyperlipidemia, and diabetes; “From Vascular Dis-
ease to a Vascular Diagnosis,” which reviewed the utility of
exercise testing, duplex ultrasound, magnetic resonance
angiography, and computed tomographic techniques; and
“From Vascular Diagnosis to Vascular Health,” which
provided state-of-the-art reviews regarding the therapeutic
roles of exercise, pharmacotherapies, percutaneous and sur-
gical PAD interventions.
NEW INSIGHTS INTO CARDIOVASCULAR RISK
These meetings highlighted the expansion of investigations
that assess the impact of both classical and non-classical risk
factors to predict cardiovascular ischemic events. Two po-
tential predictors of events have served as the focus of
increasing investigation: C-reactive protein (CRP), a
marker of systemic inflammation, and the metabolic syn-
drome, defined as abdominal obesity, high triglycerides, and
low levels of high-density lipoprotein, hypertension, and
insulin resistance or elevated fasting blood sugar values. In
2003, most cardiovascular clinicians are aware of the poten-
tial importance of CRP. The work of Mora et al. (1) at this
meeting continues to show the predictive value of an
elevated CRP value. In this work, the relevance of an
elevated CRP level was assessed in high-risk asymptomatic
individuals. These data demonstrated that with the addition
of each component of the metabolic syndrome, there was a
stepwise increase in the CRP value. Thus, the metabolic
syndrome appears to be associated with the systemic inflam-
matory response. This provides insight suggesting one
mechanism by which the metabolic syndrome may elicit an
inflammatory response and cause unstable atheroma to
create clinically recognized ischemic events.
Other new data underpin the value of CRP as a predictor
of future cardiovascular ischemic events. Albert et al. (2)
have presented an analysis that demonstrates that physical
activity is a modulator of inflammation. These data, along
with data previously shared in other venues, demonstrate
that the level of daily physical activity can predict the CRP
level, and might imply that exercise can modulate systemic
risk. A dose-response exists between the level of physical
activity and CRP level, and even relatively mild physical
activity can diminish the systemic inflammatory response
and, perhaps, the progression of arterial disease. In previous
investigations, therapeutic exercise has been shown to di-
minish inflammatory markers. Perhaps one of the best
“therapeutic anti-inflammatory interventions” is daily phys-
ical activity.
The relationship between markers of systemic atheroscle-
rosis and inflammation was also extended by the work of
Preis et al. (3). The severity of lower extremity atheroscle-
rosis, as quantified by the ankle-brachial index (ABI) in
individuals with PAD, is predictive of the degree of eleva-
tion of markers of inflammation and thrombosis. These data
demonstrated that elevations in multiple inflammatory
markers (CRP, vascular cell adhesion molecule, intercellular
adhesion molecule-1, and interleukin-6) correlate with the
severity of PAD, but that one marker of a potential
prothrombotic state (plasminogen activator inhibitor-1)
does not. As well, an elevation in the level of CRP and a
diminished ABI value together predict subsequent cardio-
vascular events. These data suggest that such indices of overt
atherosclerotic disease (as objectively indexed by the ABI
value) and inflammation might be best used together as we
attempt to better refine our risk assessment. Individuals with
both overt lower extremity atherosclerosis and elevated
inflammatory markers would be expected to suffer more
rapid disease progression, as has been demonstrated previ-
ously for coronary disease. This supposition will need to be
tested in subsequent investigations. We have known for
many years that plaque rupture is a central, but unpredict-
able event in the coronary circulation. Yet, this phenome-
non has rarely been investigated in other arterial circula-
tions. Hongo et al. (4) applied the intravascular ultrasound
technique in a PAD population being examined for possible
limb arterial revascularization. This is a novel report that has
demonstrated the characteristics of plaque rupture in a
non-coronary atherosclerotic population at risk. In this
population, nearly half of these individuals demonstrated
plaque morphology that appeared analogous to that which
has previously been demonstrated in coronary vessels.
Whether such plaque morphology can predict the progres-
sion of PAD from asymptomatic to more severe symptom
stages (e.g., claudication or critical limb ischemia) will
undoubtedly serve as a future research question.
The role of other systemic metabolic abnormalities has
continued to expand as we define the cardiovascular risk
associated with the metabolic syndrome (the association of
dyslipidemia, hypertension, insulin resistance, and obesity).
The retrospective analysis from the WOSCOPS trial, by
L’Italien et al. (5), demonstrated that the metabolic syn-
drome provides a powerful contributor to future cardiovas-
cular ischemic risk, even when the impact of other risk
factors is accounted for.
The role of the metabolic syndrome as a predictor of risk
was also demonstrated in a retrospective analysis of the
landmark Multiple Risk Factor Intervention Trial
(MRFIT). Such large cardiovascular databases continue to
generate powerful observations that were not pre hoc
defined as study goals. Cohen et al. (6) performed a
retrospective analysis of a subset of the 12,617 men partic-
ipating in MRFIT at study inception, defined by those
factors that are now known to characterize the metabolic
syndrome. These components of the metabolic syndrome, as
well as classic risk factors, were evaluated for their relative
378 Hirsch JACC Vol. 42, No. 2, 2003
ACC 2003 Annual Session Highlights July 16, 2003:375–93
contribution to predict long-term mortality. Overall, these
data demonstrated that the metabolic syndrome provides a
powerful contribution to risk. The Atherosclerosis Risk In
Communities (ARIC) epidemiologic survey has provided
abundant data that describe the burden of atherosclerosis in
our communities. A new report by Dr. Ballantyne and
colleagues, presented at the Late-Breaking Clinical Trials,
has described the predictive roles of lipoprotein-associated
phospholipase A, CRP, and other factors, and again has
demonstrated the contribution of these factors to subse-
quent ischemic events. These investigators and others have
provided data that suggest that the metabolic syndrome may
serve as a target of treatment in our effort to improve
cardiovascular outcomes in the U.S. and around the world in
the years ahead.
In addition to biochemical markers of risk, a large body of
evidence has accrued to document that early structural
abnormalities of coronary, and peripheral, arteries connote
prospective risk of clinical events. The St. Francis Heart
Study (presented by Dr. Arad and colleagues at the Late-
Breaking Clinical Trials) provided new evidence of the
predictive value of coronary calcium scores, above and
beyond that provided by serum markers or by Framingham
risk scores, to segregate risk in populations of asymptomatic
individuals. As the number of markers of risk increases, both
clinicians in practice and patients who seek to minimize
personal risk will continue to seek simple algorithms regard-
ing which “risk predictors” should be measured. Shall some
be applied, all applied, and can society afford this incremen-
tal cost? Or can we afford not to utilize our expanding ability
to predict cardiovascular risk, when we know that some
interventions, such as exercise and pharmacotherapy, can
prevent costly, morbid, and mortal events?
THE BENEFIT OF CARDIOVASCULAR
RISK REDUCTION INTERVENTIONS
These meetings continue to demonstrate the power of
large-scale clinical trials to elucidate the benefit of pharma-
cologic interventions. The Anglo-Scandinavian Cardiac
Outcomes Trial (ASCOT) study has demonstrated that
stain therapies (e.g., atorvastatin in ASCOT), applied
long-term in a hypertensive population, can offer a stunning
reduction in morbid events and reduce mortality (presented
by Dr. Sever and colleagues at the Late-Breaking Clinical
Trials). As well, evidence from the Coronary Drug Project
demonstrated that niacin decreases both rates of myocardial
infarction and total mortality in patients with the metabolic
syndrome (presented by Dr. Canner and colleagues at the
Late-Breaking Clinical Trials). These meetings provided
evidence of the cardiovascular benefits of statins, niacin,
exercise, and older lipid-modifying medications that provide
realistic hope that risk can be diminished. Despite contin-
ued concern regarding potential adverse effects of statin
medications, these data again show that profoundly benefi-
cial outcomes can be achieved in the relative absence of
significant adverse effects. Practicing physicians and the
public should feel additional reassurance that the risk-
benefit associated with use of statin medications is far
weighted toward benefit, and exemplifies how an under-
standing of a fundamental vascular biologic pathway (li-
poprotein metabolism) has improved public health.
SUMMARY AND CONCLUSIONS
The VHP track integrates the full spectrum of knowledge
“from endothelium to clinical events” to translate vascular
biology into clinical practice. The data presented at ACC’03
demonstrate that there are a series of metabolic and inflam-
matory markers that predict coronary artery and peripheral
arterial risk. This risk describes the future burden of clinical
disease and identifies individuals in whom treatment can be
effective. This year, this ability to predict risk has been
extended to non-coronary circulations such as PAD. These
data have further anchored the importance of the metabolic
syndrome and, in particular, have outlined the very large
contributions to our knowledge base derived from large
clinical trials populations, such as the MRFIT,
WOSCOPS, ASCOT, and St. Francis Heart Study popu-
lations. Vascular biology provides the foundation for under-
standing the causes of systemic atherosclerosis in all vascular
beds as well as its clinical manifestations. Cardiovascular
epidemiology and interventional clinical trials can define the
populations at risk and methods to effectively lower risk.
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